Vaccines and Immunology

Welcome Message

We are delighted to welcome global researchers, clinicians, academicians, and industry professionals to the 9^th International Conference on Vaccines and Immunology, taking place on April 23–24, 2026, in Paris, France.

As emerging infectious diseases continue to challenge global health systems, this conference brings together modern immunology and innovative vaccine approaches, aligned with the focus “Integrating Immunology and Vaccine Technologies to Combat Emerging Diseases”. Scientific discussions will explore advances that improve immune protection, while evolving vaccine technologies refine delivery methods and enhance response consistency. The programme also highlights progress in host defense, examining how pathogens interact with immune pathways and how cell communication shapes protective outcomes across populations.

Through keynote lectures, panel discussions, and interactive scientific sessions, participants will examine strategies influenced by ongoing research in immune balance and the development of adaptable vaccine platforms. These exchanges aim to strengthen interdisciplinary collaboration and support the translation of scientific insight into effective public health solutions.

Target Audience

• Immunologists
• Vaccine Researchers & Scientists
• Clinical Immunologists
• Infectious Disease Specialists
• Virologists & Microbiologists
• Public Health Professionals
• Epidemiologists
• Clinical Trial Investigators
• Vaccine Development Scientists
• Pharmaceutical & Biotechnology Professionals
• Regulatory Affairs Specialists
• Translational Researchers
• Academic Faculty & Educators
• Healthcare Policy Makers
• Biomedical Scientists
• Data Scientists in Immunology
• Graduate Students
• Postgraduate Trainees
• PhD Scholars

About Conference

The 9^th International Conference on Vaccines and Immunology, scheduled for April 23–24, 2026, in Paris, France, serves as a global scientific forum dedicated to advancing vaccine research and immunological innovation in response to emerging health threats. This conference is shaped by the theme “Integrating Immunology and Vaccine Technologies to Combat Emerging Diseases”, emphasizing the critical intersection of immune science and next-generation vaccine development in safeguarding global health.

The scientific programme spans a broad spectrum of topics influenced by progress in immunodynamics, novel vaccine engineering approaches, and the growing application of systems biology in understanding host–pathogen interactions. Discussions will also address evolving concepts in immune surveillance, data-driven vaccinology, and preparedness strategies guided by pathogen evolution across diverse populations.

Through expert lectures, panel discussions, workshops, and poster presentations, the conference fosters collaboration among clinicians, researchers, academicians, and industry leaders. It offers a dynamic platform for knowledge exchange, innovation, and collective progress toward strengthening global immunization strategies through advances in precision medicine and translational research.

Why to Attend

The 9^th International Conference on Vaccines and Immunology offers a premier international platform for professionals committed to advancing immune-based prevention and control of infectious diseases. Across two intensive scientific days, participants will explore emerging strategies in vaccine development, immune modulation, and translational immunology that are shaping modern global health responses.

This meeting provides a unique opportunity to engage with global experts and gain insights into research-driven approaches influenced by immune memory formation, innovative vaccine delivery technologies, and evolving regulatory frameworks. Discussions will emphasize how immunological precision enhances vaccine safety, efficacy, and long-term protection.

Whether you are a clinician, academic researcher, industry professional, or early-career scientist, the conference offers an ideal environment to expand expertise, exchange interdisciplinary knowledge, and stay aligned with emerging developments that are redefining vaccines and immunology worldwide.

Conference Highlights

• Global Experts in Vaccines and Immunology: Engage with internationally recognized immunologists, vaccine scientists, infectious disease experts, and public health leaders shaping global immunization strategies.
   
• Scientific Sessions on Emerging Vaccine Technologies: In-depth discussions on novel vaccine platforms, immune profiling, adjuvant innovation, and strategies to counter emerging infectious diseases.
   
• Workshops on Translational and Clinical Immunology: Expert-led sessions focused on vaccine evaluation, immune response monitoring, clinical trial design, and regulatory considerations.
   
• Innovation and Industry Showcase: Explore cutting-edge vaccine technologies, immunological tools, analytical platforms, and biotechnological solutions presented by leading industry partners.
   
• Young Researchers and Early-Career Scientists Forum: A dedicated platform for students, fellows, and early-career professionals to present research, receive expert feedback, and gain international exposure.
   
• Networking and Global Collaboration Opportunities: Connect with researchers, clinicians, policymakers, and industry professionals to foster multidisciplinary collaborations and partnerships.
   
• Awards for Excellence in Vaccines and Immunology Research: Recognition of outstanding scientific contributions through awards such as Best Research Presentation, Young Investigator Award, Best Clinical Innovation, and Best Poster Presentation.

Sessions and Tracks

Track 1: Vaccine Design and Antigen Engineering

Vaccine design focuses on engineering antigens capable of inducing strong, specific, and long-lasting immune responses. Advanced epitope mapping enables precise identification of immunodominant regions critical for immune recognition. Structural refinement minimizes loss of efficacy caused by antigenic drift and pathogen evolution. Comprehensive immunogenicity profiling supports consistent responses across genetically diverse populations. Molecular stabilization techniques improve antigen folding, storage durability, and formulation compatibility.

Antigen Engineering:

• Epitope Architecture
• Molecular Stability
• Scalable Formulation

Track 2:  Innate Immune Responses in Vaccination

Innate immune activation plays a foundational role in determining vaccine success. Engagement of pattern recognition receptors triggers rapid immune surveillance following vaccination. Balanced cytokine cascades regulate inflammation while promoting adaptive immune priming. Controlled inflammasome activation enhances protective immunity without excessive reactogenicity. Innate immune memory contributes to improved booster responses and early defense.

Innate Activation:

• Pattern Recognition
• Cytokine Signaling
• Immune Conditioning

Track 3: Adaptive Immunity and Immune Memory Formation

Adaptive immunity ensures durable vaccine-induced protection against pathogens. Vaccination stimulates clonal expansion of antigen-specific lymphocytes. Enhanced affinity maturation improves antibody specificity and neutralization efficiency. Formation of long-lived plasma cells supports rapid secondary immune responses. Coordinated cellular and humoral immunity strengthens long-term protection.

Immune Memory:

• Clonal Expansion
• Long-Term Protection
• Humoral–Cellular Balance

Track 4: Adjuvants and Immune Modulation Strategies

Adjuvants enhance vaccine efficacy by amplifying immune recognition and response strength through improved cell priming. Novel Toll-like receptor agonists improve antigen uptake and immune cell activation via enhanced receptor engagement. Controlled formulation generates a localized depot effect that supports prolonged antigen retention at the injection site. Advanced immunostimulatory complexes balance immune potency and safety by maintaining response control.

Adjuvant Science:

• Immune Stimulation
• Dose Optimization
• Safety Profiling

Track 5: Viral Vaccine Platforms and Vector Technologies

Viral vaccine platforms enable efficient antigen delivery to host immune cells through enhanced cellular entry mechanisms. Engineered vectors induce robust immune activation without disease replication by maintaining vector attenuation. Optimized transgene expression enhances intracellular antigen synthesis and supports improved protein yield. Ensuring replication incompetence improves safety in immunocompromised populations by limiting viral persistence.

Viral Platforms:

• Vector Design
• Gene Expression
• Safety Controls

Track 6: Bacterial Vaccines and Toxoid Development

Bacterial vaccines target pathogenic determinants responsible for disease progression. Detoxified toxoid inactivation kinetics preserve antigenicity while eliminating toxicity. Structural refinement improves antigen presentation efficiency. Neutralization of virulence factors enhances protective outcomes. Advanced purification ensures batch consistency and reduced endotoxin levels.

Bacterial Strategies:

• Toxoid Development
• Antigen Purification
• Potency Assurance

Track 7: mRNA Vaccines and Nucleic Acid Platforms

mRNA vaccines represent a transformative advancement in immunization technology through improved molecular stability. Lipid nanoparticle encapsulation protects RNA from enzymatic degradation while enhancing cellular uptake. Efficient ribosomal translation enables high antigen expression with improved expression consistency. Strategic nucleoside modification reduces innate immune overactivation and supports tolerance balance.

mRNA Platforms:

• Nanoparticle Delivery
• RNA Stability
• Rapid Adaptation

Track 8: Vaccine Delivery Systems and Targeting Approaches

Efficient delivery systems enhance vaccine uptake and immune engagement by improving cell access. Advanced nanocarrier systems improve antigen transport to immune cells through enhanced particle stability. Controlled release kinetics optimize immune exposure timing and support response pacing. Tissue-specific targeting enhances localized immune responses via site selectivity.

Delivery Innovation:

• Nano carriers
• Targeted Uptake
• Controlled Release

Track 9: Immunopathology and Vaccine Safety

Understanding immune-mediated adverse events is critical for vaccine safety. Dysregulated immune tolerance may lead to hypersensitivity reactions. Monitoring autoimmune activation pathways ensures long-term safety. Risk mitigation addresses immune complex formation following vaccination. Continuous surveillance supports public confidence.

Safety Monitoring:

• Immune Tolerance
• Adverse Responses
• Surveillance Systems

Track 10: Pediatric and Geriatric Immunization Strategies

Age-related immune variation influences vaccine performance across life stages. Immune immaturity affects pediatric responses, while immunosenescence reduces efficacy in older adults. Progressive thymic involution alters T-cell diversity. Decline in naïve lymphocyte reserves impacts long-term memory formation. Tailored dosing improves protection.

Age-Specific Immunization:

• Pediatric Responses
• Immunosenescence
• Booster Strategies

Track 11: Mucosal Immunity and Alternative Vaccine Routes

Mucosal vaccination targets primary pathogen entry sites, offering localized and systemic protection. Induction of secretory IgA enhances frontline immune defense at respiratory, gastrointestinal, and urogenital surfaces. Activation of mucosa-associated lymphoid tissue (MALT) improves antigen uptake and immune surveillance. Development of tissue-resident memory immune cells supports long-term localized immunity. These strategies reduce transmission, improve compliance, and strengthen barrier immunity through non-invasive delivery approaches.

Mucosal Defense:

• Secretory Immunity
• Local Memory
• Non-Invasive Routes

Track 12: Immunogenetics and Host Immune Variability

Genetic variability significantly influences individual and population-level vaccine responsiveness. Differences in HLA polymorphism affect antigen processing and presentation efficiency within the immune landscape. Variations in single nucleotide polymorphisms (SNPs) alter immune signaling pathways and cytokine responses during immune activation. Host genomic profiling enables predictive immune response modeling and stratified vaccine strategies.

Genetic Influence:

• HLA Diversity
• Genomic Profiling
• Precision Immunization

Track 13: Vaccine-Induced Cellular Immunity

Cell-mediated immunity plays a critical role in eliminating intracellular pathogens and supporting long-term protection. Activation of cytotoxic T lymphocytes (CTLs) enables efficient clearance of infected cells through cellular targeting. Balanced T-helper cell polarization coordinates immune regulation and memory formation within immune networks. Development of effector and central memory subsets enhances rapid recall responses and protective persistence.

Cellular Responses:

• Cytotoxic Function
• Helper T Cells
• Memory Subsets

Track 14: Computational Immunology and Vaccine Modeling

Computational immunology accelerates vaccine discovery by integrating biological data with predictive analytics and digital modeling. In silico epitope prediction identifies high-affinity antigen targets using algorithmic screening. Immune system simulations model complex host–pathogen interactions across virtual environments. Machine learning algorithms improve immune response forecasting and candidate selection. Integration of multi-omics datasets enables data-driven and cost-efficient vaccine design.

Computational Tools:

• Epitope Prediction
• Immune Simulation
• Data Integration

Track 15: Vaccine Biomarkers and Immune Correlates

Biomarkers are essential for evaluating vaccine efficacy, safety, and immune durability across clinical settings. Identification of immune correlates of protection enables prediction of clinical outcomes and response strength. Advanced serological profiling assesses antibody magnitude, functionality, and longevity. Monitoring cellular immune signatures provides mechanistic insight into protection through immune readouts. Biomarker-guided approaches support dose optimization and accelerate regulatory decision-making.

Immune Indicators:

• Serological Markers
• Cellular Signatures
• Response Prediction

Track 16: Emerging and Re-Emerging Infectious Diseases

Vaccines remain central to combating rapidly evolving and re-emerging infectious threats affecting global health security. Continuous monitoring of zoonotic spillover events strengthens outbreak preparedness and risk assessment. Genomic surveillance tracks pathogen evolution and mutation patterns across regions. Early assessment of antigenic shift enables timely vaccine adaptation. Coordinated global response strategies improve epidemic containment and preparedness planning.

Emerging Threats:

• Surveillance
• Genomic Monitoring
• Rapid Response

Track 17: Vaccine Manufacturing and Scale-Up Technologies

Efficient manufacturing is vital for timely and equitable vaccine distribution across supply chains. Process optimization improves production yield, consistency, and reproducibility through process control. Advanced bioreactor systems support scalable antigen expression and production efficiency. Continuous manufacturing reduces variability and shortens production timelines. Quality-by-design principles ensure compliance with international regulatory standards.

Manufacturing Science:

• Process Scale-Up
• Production Systems
• Quality Control

Track 18: Regulatory Science and Vaccine Approval Pathways

Regulatory science ensures vaccines meet rigorous safety, quality, and efficacy benchmarks within regulatory frameworks. Robust clinical evaluation frameworks support evidence-based licensure decisions. Pharmacovigilance systems enable early detection of rare adverse events through safety monitoring. Regulatory convergence harmonizes global approval processes. Transparent governance strengthens public confidence and regulatory trust.

Regulatory Pathways:

• Safety Review
• Compliance
• Post-Market Oversight

Track 19: Translational Vaccinology from Research to Practice

Translational vaccinology bridges experimental research and real-world immunization programs across healthcare systems. Integration of clinical immunogenicity data guides deployment strategies and implementation planning. Predictive dose extrapolation improves safety across populations. Early collaboration with healthcare systems accelerates implementation. Effective translation maximizes public health impact and program sustainability.

Clinical Translation:

• Validation
• Implementation
• Deployment

Track 20: Future Directions in Vaccines and Immunology

Future vaccine development emphasizes adaptability, precision, and sustainability within innovation ecosystems. Integration of systems immunology enhances disease modeling and prediction accuracy. Next-generation platforms enable rapid antigen customization and design flexibility. Artificial intelligence reshapes discovery pipelines and trial design through data automation. Personalized immunization strategies improve response variability and global preparedness.

Future Outlook:

• Next-Gen Platforms
• AI Integration
• Sustainable Immunity

Market Analysis

The global vaccines and immunology sector is experiencing sustained growth, driven by the increasing burden of emerging and re-emerging infectious diseases, expanding immunization programs, and rapid innovation in vaccine technologies. Advances in antigen engineering, adjuvant systems, and platform-based vaccine development have significantly reshaped the landscape of preventive and therapeutic immunology.

The COVID-19 pandemic accelerated investment in mRNA platforms, viral vectors, and recombinant technologies, setting a foundation for next-generation vaccine pipelines targeting respiratory viruses, antimicrobial resistance, and zoonotic pathogens. In parallel, heightened emphasis on immune correlates of protection, systems immunology, and real-world effectiveness studies continues to influence clinical development strategies.

Public–private partnerships, government-led immunization initiatives, and global funding agencies are expanding support for vaccine research, manufacturing scale-up, and equitable access. Additionally, integration of computational immunology, artificial intelligence, and predictive immune modeling is improving target identification and clinical trial efficiency. These factors collectively position vaccines and immunology as a high-impact, rapidly evolving global health market.

Global Vaccine Market Growth: 

This graph illustrates the steady expansion of the global vaccine market from 2020 to 2026. The upward trend reflects growing demand for prophylactic and therapeutic vaccines, increased awareness of immunization, and continuous innovation in vaccine platforms. Market growth is further supported by advancements in immunogenicity optimization, improved cold-chain logistics, and broader adoption of combination vaccines across pediatric, adult, and geriatric populations. The data highlights the long-term commercial and public health significance of vaccine development worldwide.


         
 

Growth in Immunology and Vaccine R&D Investment:

This graph represents the increasing global investment in immunology and vaccine research and development. Rising R&D expenditure underscores the strategic focus on translational immunology, host–pathogen interaction studies, and development of novel vaccine candidates. Investment growth is driven by expanding clinical pipelines, emphasis on immune modulation, and the need for rapid-response platforms to address emerging disease threats. The trend demonstrates strong confidence from governments, biotechnology companies, and global health organizations in the future of immune-based interventions.

Abstract Submission and Registration

Immunologists, vaccine researchers, clinicians, infectious disease specialists, public health professionals, academicians, and industry experts are invited to submit original scientific contributions to the 9^th International Conference on Vaccines and Immunology, scheduled for April 23–24, 2026, in Paris, France. Submissions may include original research abstracts, clinical studies, translational research, case reports, review articles, poster presentations, or e-posters aligned with the conference theme Integrating Immunology and Vaccine Technologies to Combat Emerging Diseases and the listed scientific tracks.

The conference encourages high-quality submissions addressing advances in vaccine platforms, immune response mechanisms, emerging infectious diseases, and translational immunology.

Abstract Guidelines

• All abstracts must be submitted in English.
• The abstract should not exceed 500 words.
• The title should be written in sentence case and clearly reflect the focus of the study.
• Provide the full name, affiliation, and designation of the presenting author and all co-authors.
• Include a short biography of the presenting author (maximum 150 words) along with a professional photograph.
• Submissions may focus on vaccines and immunology, including immune correlates of protection, antigen design, adjuvant development, clinical vaccinology, immunogenetics, emerging pathogens, or related research areas.

Review Process

All submitted abstracts will be evaluated by the Scientific Review Committee based on scientific merit, originality, and relevance. Authors will be notified of acceptance, required revisions, or presentation format via email, typically within 24–48 hours of submission. Accepted abstracts will be scheduled for oral presentations, poster sessions, or workshops according to scientific relevance.

Publication

Accepted abstracts will be included in the official conference proceedings and may be considered for publication in associated scientific journals, conference compendiums, or vaccines and immunology–focused publications.

Abstract Submission Link

https://worldvaccines.conferenceseries.com/abstract-submission.php

Registration

Upon abstract acceptance, participants are required to complete their conference registration through the official registration portal. Early registration is highly recommended to confirm participation, gain access to scientific sessions, workshops, networking opportunities, and receive the official conference certificate.

Registration grants access to keynote lectures, technical sessions, poster presentations, and discussions addressing adaptive immune responses and next-generation vaccine technologies.

Registration Link

https://worldvaccines.conferenceseries.com/registration.php

Visa Guidelines

The organizing committee of the 9^th International Conference on Vaccines and Immunology 2026 does not directly process visas for France. However, the committee provides all necessary supporting documents to assist participants with their visa application process.

Upon request, the following documents can be issued to support your visa application:

• Official Letter of Invitation
• Letter of Abstract Acceptance (if applicable)
• Registration Confirmation and Payment Receipt

Visa requirements vary depending on the applicant’s country of residence and the regulations of the French Embassy or Consulate in their region. Participants are strongly advised to apply for their visa well in advance of the conference dates to avoid delays.

Letter of Invitation

The Letter of Invitation confirms your accepted abstract and/or completed registration for the conference. This letter is issued in English and may be submitted as supporting documentation for your visa application.

Please note that issuance of an invitation letter does not guarantee visa approval. All visa decisions are made solely by French immigration authorities and respective embassies or consulates.

Contact for Visa Support

For visa-related assistance or to request official supporting documents, please contact:
meevents@memeetings.com

Past Conference

The 8^th International Conference on Vaccines and Immunology was held in 2025 in Paris, France, bringing together a diverse international community of immunologists, vaccinologists, infectious disease specialists, public health professionals, academic researchers, and biotechnology industry representatives. The conference served as a global platform for exchanging scientific knowledge and fostering collaboration across disciplines involved in vaccine research and immune science.

Conference Statistics & Participation Highlights

• Total Participants: 250+ delegates
• Countries Represented: 30+ countries across Europe, Asia-Pacific, North America, Middle East, and Africa
• Scientific Contributions: 180+ abstracts submitted
• Presentations:
  • 60+ Oral Presentations
  • 90+ Poster & E-Poster Presentations
• Keynote & Plenary Speakers: 25+ internationally recognized experts
• Workshops & Special Sessions: 10+ interactive sessions

Scientific Overview

The conference addressed contemporary challenges and emerging solutions in vaccines and immunology, with a strong emphasis on immune protection, vaccine innovation, and global preparedness against emerging and re-emerging infectious diseases. Scientific discussions explored advances in antigen engineering, immune response profiling, systems immunology, and next-generation vaccine platforms.

Key sessions focused on vaccine safety evaluation, immune correlates of protection, adjuvant optimization, and translational vaccinology. Presenters shared cutting-edge research on host–pathogen interactions, immune memory dynamics, and population-level immunization strategies aimed at strengthening public health resilience.

Key Highlights

• In-depth sessions on emerging infectious diseases, pandemic preparedness, and rapid vaccine development frameworks
• Scientific presentations on novel vaccine delivery systems, including nanoparticle and mucosal platforms
• Discussions on immune biomarkers, immunogenicity assessment, and real-world vaccine effectiveness
• Workshops emphasizing regulatory science, clinical trial design, and manufacturing scalability
• Strong engagement from early-career researchers through poster sessions and young investigator forums

Collaborative Impact

The conference facilitated high-level scientific exchange and collaboration through networking sessions, panel discussions, and interactive workshops. Participants valued the opportunity to connect across disciplines, fostering partnerships between academia, healthcare institutions, and the biotechnology and pharmaceutical sectors.

Overall, the 8^th International Conference on Vaccines and Immunology (2025) highlighted the dynamic progress of immunological research and reinforced the critical role of interdisciplinary collaboration in advancing vaccine science and global disease prevention.

Past Conference Themes and Focus Areas

In addition to the primary event, several vaccine- and immunology-focused scientific meetings held in 2025 contributed to the broader global research dialogue:

• A European scientific congress focused on vaccines and infectious diseases, addressing pandemic preparedness, antimicrobial resistance, and immunization equity.
• A hybrid international meeting in Asia-Pacific emphasizing precision vaccinology, immune profiling, and translational immunology.
• Specialty conferences exploring vaccine delivery technologies, mucosal immunity, and digital immunization surveillance, expanding perspectives on next-generation vaccine development.

Collectively, these events reflect strong global momentum in vaccines and immunology research, reinforcing shared priorities in innovation, preparedness, and evidence-based immunization strategies.

Upcoming Conference at a Glance:

The 9^th International Conference on Vaccines and Immunology, scheduled for April 23–24, 2026, in Paris, France, will bring together global experts in immunology, vaccinology, infectious diseases, public health, and biotechnology to exchange knowledge and advance collaborative research. Centered on the theme Integrating Immunology and Vaccine Technologies to Combat Emerging Diseases, the conference will highlight scientific progress in immune response mechanisms, innovative vaccine platforms, translational research, and preparedness strategies for emerging and re-emerging pathogens. Through keynote lectures, scientific sessions, and interactive discussions, the meeting aims to accelerate the translation of immunological discoveries into effective vaccine solutions that strengthen global health resilience.